Heart Valve Technology

This channel includes news and new device innovations about heart valve technologies, including the aortic valve, mitral valve, pulmonic valve, and tricuspid valve. This includes information on transcatheter valve technologies like transcatheter aortic valve replacement (TAVR, or implantation TAVI), transcatheter mitral valve repair or replacement (TMVR), transcatheter and surgical valve repairs, and surgical replacement valves. Newer devices are now being used for transcatheter tricuspid valve repair replacement (TTVR). 

The U.S. Food and Drug Administration (FDA) has cleared the company's Portico with FlexNav transcatheter aortic valve replacement (TAVR) system to treat people with symptomatic, severe aortic stenosis who are at high or extreme risk for open-heart surgery. 
Feature | Structural Heart Occluders | By Dave Fornell, Editor
FDA Clears Abbott Portico TAVR System to Treat Aortic Valve Disease

September 20, 2021 — Abbott announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Portico ...

Home September 20, 2021
Home
Non-invasive evaluation of heart valves using echocardiography first, and other cardiac imaging techniques when needed, is the key evaluation of heart valves in the new ESC and European Association for Cardio-Thoracic Surgery (EACTS) Guidelines for the management of valvular heart disease. Photo by Dave Fornell.
News | Structural Heart
New European Guidelines on Valvular Heart Disease Published

September 13, 2021 — The European Society of Cardiology (ESC) and European Association for Cardio-Thoracic Surgery ...

Home September 13, 2021
Home
The anticoagulant edoxaban (Savaysa) may be just as effective as warfarin for preventing heart attack or stroke in patients with AFib who undergo transcatheter aortic valve replacement (TAVR), according to an ESC late-breaking trial.
News | Antiplatelet and Anticoagulation Therapies
Edoxaban May Be Effective Treatment for Atrial Fibrillation After TAVR 

September 1, 2021 – The anticoagulant edoxaban (Savaysa) may be just as effective as warfarin for preventing heart ...

Home September 01, 2021
Home
Leveraging Vivasure Medical’s PerQseal vascular closure device technology, PerQseal Blue consists of an intravascular patch designed to seal the vessel from the inside, returning the vein to its natural state after it dissolves over time, so no foreign bodies are left behind.
News | Vascular Closure Devices
Vivasure Medical is Developing a Sutureless Venous Closure Device for Transcatheter Valve Procedures

July 15, 2021 — Vivasure Medical announced its development program for PerQseal Blue, a sutureless and fully ...

Home July 15, 2021
Home
Videos | Structural Heart
VIDEO: Acurate neo2 TAVR Valve Performs Well in Latest Trials

Doctor Andreas Ruck, interventional cardiologist and head of the mitral/tricuspid program, Karolinska University ...

Home July 14, 2021
Home
The Xeltis synthetic polymer restorative pulmonary valve is implanted surgically and acts as a scaffold for the patient's own cells to proliferate. The valve and conduit then bioresorbs over time, leaving behind a new valve made from the patient's own cells. The hope is this will reduce or eliminate the need for numerous repeat surgeries as a pediatric patient grows.
Feature | Heart Valve Technology
Xeltis Begins Pivotal Trial for Pulmonary Valve That Grows With the Patient

July 8, 2021 – Xeltis announced it started the first pivotal trial for a synthetic polymer restorative pulmonary valve ...

Home July 08, 2021
Home
The balloon inflation to deploy an Edwards Lifesciences Sapien 3 TAVR valve in a failed surgical tricuspid valve. This valve-in-valve (VIV) procedures was performed at Beaumont in a 34-year-old female patient who was determined to be too high of a surgical risk for SAVR.
News | Structural Heart
Beaumont Performs Rare Tricuspid Transcatheter Valve-in-valve Procedure

June 29, 2021 – Cardiologists at Beaumont Health successfully replaced a 34-year-old woman’s tricuspid valve in a rare ...

Home June 29, 2021
Home
Boston Scientific Makes a Comeback With Positive Clinical Data With its Second Iteration Acurate neo2 TAVR Valve
Blog | Structural Heart
Boston Scientific Makes a Comeback With Positive Clinical Data for its Second Iteration Acurate neo2 TAVR Valve

It is brutal and very expensive to bring a new transcatheter valve to market. Boston Scientific invested vast amounts of ...

Home June 08, 2021
Home
The 30-day outcomes from the TRISCEND study of the transfemoral Evoque tricuspid valve replacement system demonstrated technical feasibility and an acceptable safety profile, along with improvements in tricuspid regurgitation (TR) and symptoms in patients with clinically significant TR.
News | Structural Heart
Edwards LifeSciences Reports Positive Clinical Updates on its Transcatheter Mitral and Tricuspid Valves

June 7, 2021 — Edwards Lifesciences recently announced that clinical results from the company's transcatheter mitral and ...

Home June 07, 2021
Home
The HLT, Bracco, Meridian II TAVR Valve System.
Feature | Structural Heart | Dave Fornell, Editor
Bracco Moving Forward With HLT Meridian TAVR Valve

June 2, 2021 — The startup company HLT is a part of the Bracco Group, which is developing a new transcatheter aortic ...

Home June 02, 2021
Home
The LivaNova Percelval sutureless aortic valve and Solo Smart surgical aortic valve are part of heart valve portfolio the company sold off June 1 to Gyrus Capital and Corcym..
News | Heart Valve Technology
LivaNova Sells Heart Valve Business to Gyrus Capital

June 2, 2021 – LivaNova announced June 1 it successfully completed the initial closing of the divestiture of its heart ...

Home June 02, 2021
Home
Videos | Congenital Heart
VIDEO: Advances in Congenital Heart Therapy Technologies

Tom Jones, M.D., director, cardiac catheterization laboratories, Seattle Children’s Hospital, explains some of the new ...

Home May 26, 2021
Home
The Acurate neo2 TAVR valve design enhancements include a 60% larger outer sealing skirt to conform to challenging anatomies. This has minimized paravalvular leaks and imporved clinical outcomes compared to the previous-generation Acurate neo Aortic Valve System. #EuroPCR #EuroPCR21 #EuroPCR2021
Feature | Structural Heart
Acurate neo2 TAVR Valve Demonstrate Reduced Paravalvular Leak and Low Permanent Pacemaker Rates 

May 26, 2021 — Data presented at hotline and late-breaking trial sessions at the EuroPCR 2021 congress for the updated ...

Home May 26, 2021
Home
An Edward Lifesciences Sapien TAVR valve during an implant procedure on angiography. There are still questions on how to best anticoagulate TAVR patients and the ATLANTIS study found Eloquis is not a good solution.
News | Structural Heart
TAVR Anticoagulation With Apixaban Not Superior to Standard Care

May 15, 2021 — The anticoagulant apixaban (Eliquis) was not superior to standard of care following transcatheter aortic ...

Home May 15, 2021
Home
Explaining the Emory TMVR angle. Discordance between mitral annular centerline (yellow lines) and valve orientation imposed by guidewire position within the LV apex (red dashed lines). (B) Valve intrinsic angle (α) is determined by external skirt height. (C) When annular-apical “Emory” angle (red curves) exceeds α (blue curve), annular skirt apposition is not possible, causing PVL (red arrows). (D) The valve is oriented perpendicular to the annual plane using an exteriorized apical guidewire.
Feature | Structural Heart | By Dave Fornell, Editor
The Emory Angle Can Help Eliminate Paravalvular Leak in Transcatheter Mitral Interventions

The mitral valve anatomy is extremely complex, which has caused many challenges for transcatheter mitral valve ...

Home May 13, 2021
Home
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now